by Madaline Spencer | Feb 4, 2026
Shervin Assassi, MD, Director, Division of Rheumatology at McGovern Medical School, discusses the approval of Jascayd (nerandomilast) tablets for treatment of patients with progressive pulmonary fibrosis (PPF). PPF is a subcategory of interstitial lung...
by Madaline Spencer | Feb 3, 2026
Lynn Malec, MD, Versiti Blood Research Institute and Medical College of Wisconsin, discusses results from the XTEND-ed clinical trial evaluating efanesoctocog alfa for the treatment of patients with hemophilia A. Hemophilia A is an inherited bleeding...
by Madaline Spencer | Feb 2, 2026
Richard Nowak, MD, Director of the Myasthenia Gravis Clinic at Yale University, discusses the recent U.S. Food and Drug Administration (FDA) approval of Uplizna (inebilizumab) for the treatment of generalized myasthenia gravis (gMG) in adults who are...
by Madaline Spencer | Jan 30, 2026
The US Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of adults with newly diagnosed multiple myeloma (MM) who are ineligible for...
by Madaline Spencer | Jan 30, 2026
Hartmut Döhner, MD, Professor of Medicine and Medical Director of the Department of Hematology and Oncology, Ulm University, Germany, discusses bleximenib combination therapy for treatment of patients with acute myeloid leukemia (AML). AML is a cancer...
